Skip to content
Screener

CareDx CDNA Reportable Segment — Gain (Loss) from Litigation Settlement

Similar metrics at other companies

Amneal Pharmaceuticals, Inc. logo
AMRXAvKARE — Gain (Loss) from Litigation Settlement
$0
Amneal Pharmaceuticals, Inc. logo
AMRXSpecialty — Gain (Loss) from Litigation Settlement
$0
Altisource Portfolio Solutions logo
ASPSOrigination — Gain (Loss) from Litigation Settlement
$0
Amneal Pharmaceuticals, Inc. logo
AMRXAffordable Medicines — Gain (Loss) from Litigation Settlement
-$8.06M-2,166%
Altisource Portfolio Solutions logo
ASPSServicer and Real Estate — Gain (Loss) from Litigation Settlement
-$1.88M
Cracker Barrel Old Country Store logo
CBRLSingle Reportable — Gain Loss Related To Litigation Settlement
$47.42M

Other financials

Income statement

See full
Revenue$117.7M+39.0%
Operating income$1.2M+109%
Net income$2.8M+127%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$78.5M-12.1%
Total debt$24.5M-19.1%
Total equity$313.5M-17.3%
Total assets$411.1M-16.0%

Cash flow

See full
Operating cash flow$4.3M+116%
CapEx$3.8M+134%
Free cash flow$514.0K+102%

Valuation

See full
Market cap$2.42B+279%
Enterprise value$2.36B+295%
P/S5.9×+4.0×

Profitability

See full
Gross margin65.5%
Operating margin-3.9%-18.3pp
Net margin-2%-19.9pp
FCF margin-0%0.0pp

Returns & leverage

See full
Return on equity-2.4%-21.9pp
Debt / equity0.1×0.0×
Current ratio3.4×-0.7×

Where this comes from

Reported directly by CareDx in its filing.

Tagged under the XBRL concept us-gaap:GainLossRelatedToLitigationSettlement.

The source filing: CareDx’s 10-Q, filed April 28, 2026.

Filed
Apr 28, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001217234-26-000033
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Research and development21,41618,524
Sales and marketing30,37322,991
General and administrative30,48422,769
Litigation settlement expense6005,360
Total operating expenses116,50298,059
Income (loss) from operations1,198(13,374)
Other income:
Interest income, net1,9092,784

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is CareDx's reportable segment — gain (loss) from litigation settlement?
CareDx (CDNA) reported reportable segment — gain (loss) from litigation settlement of -$600K in Q1 2026.
How has CareDx's reportable segment — gain (loss) from litigation settlement changed year-over-year?
CareDx's reportable segment — gain (loss) from litigation settlement increased by 88.8% year-over-year, from -$5.36M to -$600K.
What is the long-term trend for CareDx's reportable segment — gain (loss) from litigation settlement?
Over 2 years (2023 to 2025), CareDx's reportable segment — gain (loss) from litigation settlement has grown at a -75.6% compound annual growth rate (CAGR), from -$96.3M to -$5.71M.
What does reportable segment — gain (loss) from litigation settlement mean?
Captures the financial impact of legal settlements, including both gains from favorable outcomes and losses from adverse judgments or agreements. These items are typically non-recurring and can significantly distort the segment's reported operating performance in a given period.

Ask your AI about CareDx's reportable segment — gain (loss) from litigation settlement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude